# SAM #BAA-23-100-SOL-00004

Award for development of SCY-247, a novel antifungal for invasive candidiasis and fungal disease prophylaxis

**Buyer:** ASPR BARDA
**Posted:** September 25, 2026
**Identifier:** BAA-23-100-SOL-00004
**NAICS:** 541715, 541714

This award from the Biomedical Advanced Research and Development Authority (BARDA), under the Department of Health and Human Services, supports the development of a novel antifungal drug.
- Government Buyer:
  - Department of Health and Human Services
  - Office of Assistant Secretary for Preparedness and Response
  - Biomedical Advanced Research and Development Authority (BARDA)
- OEM and Vendor:
  - Scynexis, Inc. (manufacturer and awardee)
- Products/Services Requested:
  - Development of SCY-247, a novel antifungal drug
  - Target indications: invasive candidiasis treatment and prophylaxis of invasive fungal disease
  - Formulations: oral and intracavitary (IC)
  - Phase 1 clinical trials
- Unique/Notable Requirements:
  - Focus on advancing a new pharmaceutical agent for critical infectious disease indications
  - No specific part numbers or purchase quantities; this is a research and development award
- Award Value:
  - $213,943,726
- No additional product or service line items listed

[View original listing](https://sam.gov/opp/5d2b1c5f6d094d72ad9916f20fc33ed3/view)